Related Experiment Video
Updated: Mar 16, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
Reversal agents for NOACs: Connecting the dots
Jamshed Dalal1, Abhay Bhave2, Gaurav Chaudhry3
1Director, Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Rao Saheb Achutrao Patwardhan Marg, Four Bunglows, Andheri (W), Mumbai 400053, India.
New reversal agents for Non-vitamin K Oral Anticoagulants (NOACs) are in development. These agents will improve management of bleeding events and emergency surgeries, increasing confidence in NOAC use.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Background:
- Non-vitamin K Oral Anticoagulants (NOACs) are increasingly prescribed.
- Managing bleeding complications and emergency procedures in patients on NOACs presents challenges.
Purpose of the Study:
- To review the current development of specific reversal agents for NOACs.
- To highlight the clinical implications of these emerging therapies.
Main Methods:
- A systematic literature search was performed.
- Databases searched included Medline, Embase, and the Cochrane register.
Main Results:
- Development of specific reversal agents for NOACs is progressing.
- These agents aim to rapidly counteract NOAC activity.
Conclusions:
- Novel reversal agents for NOACs address a critical unmet need.
- They will facilitate management of major bleeds and urgent surgeries.
- Increased confidence in NOACs may broaden their clinical application.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

